BACKGROUND AND AIM: Primary sclerosing cholangitis (PSC) typically develops in middle-age adults. Little is known about phenotypic differences when PSC is diagnosed at various ages. Therefore, we sought to compare the clinical characteristics of a large PSC cohort based on the age when PSC was diagnosed. METHODS: We performed a multicenter retrospective review to compare the features of PSC among those diagnosed between 1-19 (n = 95), 20-59 (n = 662), and 60-79 years (n = 102). RESULTS: Those with an early diagnosis (ED) of PSC were more likely to have small-duct PSC (13%) than those with a middle-age diagnosis (MD) (5%) and late diagnosis (LD) groups (2%), P < 0.01, and appeared to have a decrease risk of hepatobiliary malignancies: ED versus MD: hazard ratio (HR), 0.25; 95% confidence interval (CI) 0.06-1.03, and ED versus LD: HR, 0.07; 95% CI 0.01-0.62. Cholangiocarcinoma was diagnosed in 78 subjects (ED n = 0, MD n = 66, and LD n = 12) and was more likely to be diagnosed within a year after the PSC diagnosis among those found to have PSC late in life: ED 0% (0/95), MD 2% (14/662), and LD 6% (6/102), P = 0.02. Similarly, hepatic decompensation was more common among those with LD-PSC versus younger individuals: LD versus MD: HR, 1.64; 95% CI 0.98-2.70, and LD versus ED: HR, 2.26; 95% CI 1.02-5.05. CONCLUSIONS: Those diagnosed with PSC early in life are more likely to have small-duct PSC and less likely to have disease-related complications. Clinicians should be vigilant for underlying cholangiocarcinoma among those with PSC diagnosed late in life.
BACKGROUND AND AIM: Primary sclerosing cholangitis (PSC) typically develops in middle-age adults. Little is known about phenotypic differences when PSC is diagnosed at various ages. Therefore, we sought to compare the clinical characteristics of a large PSC cohort based on the age when PSC was diagnosed. METHODS: We performed a multicenter retrospective review to compare the features of PSC among those diagnosed between 1-19 (n = 95), 20-59 (n = 662), and 60-79 years (n = 102). RESULTS: Those with an early diagnosis (ED) of PSC were more likely to have small-duct PSC (13%) than those with a middle-age diagnosis (MD) (5%) and late diagnosis (LD) groups (2%), P < 0.01, and appeared to have a decrease risk of hepatobiliary malignancies: ED versus MD: hazard ratio (HR), 0.25; 95% confidence interval (CI) 0.06-1.03, and ED versus LD: HR, 0.07; 95% CI 0.01-0.62. Cholangiocarcinoma was diagnosed in 78 subjects (ED n = 0, MD n = 66, and LD n = 12) and was more likely to be diagnosed within a year after the PSC diagnosis among those found to have PSC late in life: ED 0% (0/95), MD 2% (14/662), and LD 6% (6/102), P = 0.02. Similarly, hepatic decompensation was more common among those with LD-PSC versus younger individuals: LD versus MD: HR, 1.64; 95% CI 0.98-2.70, and LD versus ED: HR, 2.26; 95% CI 1.02-5.05. CONCLUSIONS: Those diagnosed with PSC early in life are more likely to have small-duct PSC and less likely to have disease-related complications. Clinicians should be vigilant for underlying cholangiocarcinoma among those with PSC diagnosed late in life.
Authors: Michael P Manns; Albert J Czaja; James D Gorham; Edward L Krawitt; Giorgina Mieli-Vergani; Diego Vergani; John M Vierling Journal: Hepatology Date: 2010-06 Impact factor: 17.425
Authors: Annika Bergquist; Anders Ekbom; Rolf Olsson; Dan Kornfeldt; Lars Lööf; Ake Danielsson; Rolf Hultcrantz; Stefan Lindgren; Hanne Prytz; Hanna Sandberg-Gertzén; Sven Almer; Fredrik Granath; Ulrika Broomé Journal: J Hepatol Date: 2002-03 Impact factor: 25.083
Authors: Kirsten Boonstra; Rinse K Weersma; Karel J van Erpecum; Erik A Rauws; B W Marcel Spanier; Alexander C Poen; Karin M van Nieuwkerk; Joost P Drenth; Ben J Witteman; Hans A Tuynman; Anton H Naber; Paul J Kingma; Henk R van Buuren; Bart van Hoek; Frank P Vleggaar; Nan van Geloven; Ulrich Beuers; Cyriel Y Ponsioen Journal: Hepatology Date: 2013-10-17 Impact factor: 17.425
Authors: Mark Deneau; M Kyle Jensen; John Holmen; Marc S Williams; Linda S Book; Stephen L Guthery Journal: Hepatology Date: 2013-08-13 Impact factor: 17.425
Authors: Elisabeth M G de Vries; Junfeng Wang; Mariska M G Leeflang; Kirsten Boonstra; Rinse K Weersma; Ulrich H Beuers; Ronald B Geskus; Cyriel Y Ponsioen Journal: Liver Int Date: 2016-04-04 Impact factor: 5.828
Authors: Einar Björnsson; Rolf Olsson; Annika Bergquist; Stefan Lindgren; Barbara Braden; Roger W Chapman; Kirsten M Boberg; Paul Angulo Journal: Gastroenterology Date: 2008-01-17 Impact factor: 22.682
Authors: Zeinab Bakhshi; Moira B Hilscher; Gregory J Gores; William S Harmsen; Jason K Viehman; Nicholas F LaRusso; Andrea A Gossard; Konstantinos N Lazaridis; Keith D Lindor; John E Eaton Journal: J Gastroenterol Date: 2020-01-13 Impact factor: 7.527
Authors: Aldo J Montano-Loza; Jessica R Allegretti; Angela Cheung; Maryam Ebadi; David Jones; Nanda Kerkar; Cynthia Levy; Sumera Rizvi; John M Vierling; Fernando Alvarez; Wayne Bai; Susan Gilmour; Aliya Gulamhusein; Orlee Guttman; Bettina E Hansen; Sonya MacParland; Andrew Mason; Fernanda Onofrio; Pere Santamaria; Ashley Stueck; Mark Swain; Catherine Vincent; Amanda Ricciuto; Gideon Hirschfield Journal: Can Liver J Date: 2021-11-11
Authors: John E Eaton; Mette Vesterhus; Bryan M McCauley; Elizabeth J Atkinson; Erik M Schlicht; Brian D Juran; Andrea A Gossard; Nicholas F LaRusso; Gregory J Gores; Tom H Karlsen; Konstantinos N Lazaridis Journal: Hepatology Date: 2018-12-28 Impact factor: 17.425
Authors: Guri Fossdal; Anders B Mjelle; Kristine Wiencke; Ida Bjørk; Odd Helge Gilja; Trine Folseraas; Tom Hemming Karlsen; William Rosenberg; Lasse M Giil; Mette Vesterhus Journal: JHEP Rep Date: 2021-07-02